Transitional Cell Carcinoma of the Bladder Following Augmentation Cystoplasty for the Neuropathic Bladder

Soergel, Trevor M.; Cain, Mark P.; Misseri, Rosalia; Gardner, Thomas A.; Koch, Michaël; Rink, Richard C.

doi:10.1097/01.ju.0000140194.87974.56

Cited by 207 publications

(115 citation statements)

References 10 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…61 For those three patients, the ages at augmentation were 8, 20 and 24 years, and the ages at TCC diagnosis were 29, 37 and 44 years, respectively. 62 This observation, supported by findings at other centres, 63 is an important one, as these cancers will be seen by adult urologists, not the pediatric specialists who follow them at and around the time of their augmentations.…”

Section: Transitional Cell Carcinoma Of the Bladdermentioning

confidence: 50%

Highlights of the University of Toronto Urology Update 2014

Herschorn

2015

CUAJ

View full text Add to dashboard Cite

At the University of Toronto Urology Update 2014, a faculty of Canadian and American experts presented a series of lectures covering a range of topics in the field of urology. Areas of focus included prostate cancer (PCa), functional urology, erectile dysfunction (ED), and surgical topics (e.g., percutaneous nephrolithotomy [PCNL]). Prostate cancer screening in 2014: The debate rages on Highlights of presentations by Drs. Neil Fleshner, Girish Kulkarni, Anthony Miller and H. Ballentine CarterThe utility of the serum prostate-specific antigen (PSA) test for the early detection of PCa has been the subject of vigorous debate among clinicians, researchers and policy-makers. As discussed at Urology Update 2014, authors of current and recent guidelines still do not agree on whether or not screening should be offered on a population basis.

show abstract

Section: Transitional Cell Carcinoma Of the Bladdermentioning

confidence: 50%

Highlights of the University of Toronto Urology Update 2014

Herschorn

2015

CUAJ

View full text Add to dashboard Cite

show abstract

“…Augmentation with bowel has been associated with a bladder cancer incidence of 1.2% to 3.8%. 15 The most interesting finding from these studies was that the bladder malignancies, regardless of augmentation, were more advanced stage and invasive, which for reasons unknown, differs markedly from the general population. Thus, it is of paramount importance that spina bifida patients continue regular urologic follow-up into adulthood.…”

Section: Discussionmentioning

confidence: 82%

Complications following breast cancer therapy in the adult spina bifida population: A case report

Hoy

Metcalfe

2013

CUAJ

View full text Add to dashboard Cite

Survival to adulthood in spina bifida has greatly increased with the advent of modern therapies. With this prolonging of life expectancy, patients are exposed to the risk of adult onset malignancies and the complications of subsequent treatment. We present the case of a 66-year-old woman born with a terminal lipomyelomeningocele, presenting with new fecal incontinence and a desire to undivert her ileal conduit. The deterioration was attributed to chemotherapy for breast cancer. We highlight the urologic challenges of breast cancer management in the neurogenic bowel population, as well as the utility of an adult spina bifida clinic. To the best of our knowledge, this is the first case report of a spina bifida patient presenting with fecal and urinary complications from breast cancer chemotherapy.

show abstract

“…However, this strategy is associated with early and longterm complications, including bowel resection and anastomosis, urolithiasis, excessive mucous production, bowel obstruction, metabolic abnormalities, and secondary malignancies. 13,14 Tissue engineering may provide a novel method for urinary diversion without intestine substitution.…”

Section: Discussionmentioning

confidence: 99%

Tissue-engineered tubular substitutions for urinary diversion in a rabbit model

Meng

Liao

Yang

et al. 2015

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

Clinically, autologous gastrointestinal segments are traditionally used for urinary diversion. However, this procedure often causes many serious complications. Tissue engineering may provide an alternative treatment method in urinary diversion. This research aims to produce tissue-engineered tubular substitutions by using homologous adipose-derived stem cells, smooth muscle cells, and bladder acellular matrix in developing urinary diversion in a rabbit model. Adipose-derived stem cells and smooth muscle cells of rabbit were obtained and cultured in vitro. These cultured adipose-derived stem cells and smooth muscle cells were seeded onto the two sides of the bladder acellular matrix and then incubated for seven days. The cell-seeded matrix was used to build tissue-engineered tubular substitutions, which were then implanted and wrapped into the omentum in vivo for two weeks to promote angiogenesis. In the experimental group, the bladder of 20 rabbits was totally resected, and the above tissue-engineered tubular substitutions were used for urinary diversion. In the control group, bladder acellular matrix tubular substitutions with unseeded cells were implanted into the omentum and were used as urinary diversion on another five rabbits with the same process. The implants were harvested, and histological examination was conducted at 2, 4, 8, and 16 weeks after operation. Intravenous urography assessment was performed at 16 weeks postoperatively. All the rabbits were alive in the experimental group until they were sacrificed. Histological analysis of the construct displayed the presence of multilayer urothelial cells on the luminal side and organized smooth muscle tissue on the other side, and different diameters of neovascularization were clearly identified in the substitutions obtained. No leakage, stricture, or obstructions were noted with intravenous urography assessment. All the animals in the control group died within two weeks, and urine leakage, scar formation, and inflammation were detected through autopsy. This study demonstrates the feasibility of tissue-engineered tubular substitutions constructed using homologous adipose-derived stem cells, smooth muscle cells, and bladder acellular matrix for urinary diversion in a rabbit model.

show abstract

Transitional Cell Carcinoma of the Bladder Following Augmentation Cystoplasty for the Neuropathic Bladder

Abstract: This study supports the hypothesis that bladder augmentation appears to be an independent risk factor for TCC, with a lag time of less than 20 years. We recommend endoscopic surveillance of all patients with a history of bladder augmentation beginning 10 years after initial surgery.

Cited by 207 publications

References 10 publications

Highlights of the University of Toronto Urology Update 2014

Highlights of the University of Toronto Urology Update 2014

Complications following breast cancer therapy in the adult spina bifida population: A case report

Tissue-engineered tubular substitutions for urinary diversion in a rabbit model

Contact Info

Product

Resources

About